William Blair Issues Negative Outlook for Medpace Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – William Blair decreased their Q3 2025 earnings per share (EPS) estimates for shares of Medpace in a research note issued to investors on Tuesday, February 11th. William Blair analyst M. Smock now forecasts that the company will earn $2.99 per share for the quarter, down from their prior forecast of $3.18. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace’s Q4 2025 earnings at $2.93 EPS, FY2025 earnings at $12.12 EPS, Q1 2026 earnings at $3.38 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.50 EPS and Q4 2026 earnings at $3.57 EPS.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%.

A number of other analysts have also recently issued reports on the company. Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Stock Up 1.8 %

Shares of NASDAQ MEDP opened at $342.41 on Thursday. The stock has a market cap of $10.64 billion, a PE ratio of 29.98, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace has a 52-week low of $302.01 and a 52-week high of $459.77. The business has a 50-day moving average price of $343.70 and a 200 day moving average price of $348.88.

Institutional Trading of Medpace

Several hedge funds have recently modified their holdings of MEDP. R Squared Ltd acquired a new stake in shares of Medpace in the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in shares of Medpace in the 4th quarter valued at approximately $31,000. Stone House Investment Management LLC acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $33,000. Ashton Thomas Securities LLC acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $37,000. Finally, Jones Financial Companies Lllp lifted its holdings in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after buying an additional 110 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.